Related Experiment Video

Updated: Oct 4, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.4K

Correlation of Antithrombin Functional Status and Levels with Liver Fibrosis in Patients with Hepatitis C

Muhammad Saboor, Asghar Khan, Hassan A Hamali

    Clinical Laboratory
    |February 10, 2022
    PubMed

    Insights

    Antithrombin (AT) levels are normal in early liver fibrosis but decrease significantly in advanced stages of chronic liver disease with hepatitis C. This indicates fibrosis severity impacts AT status.

    Area of Science:

    • Hepatology
    • Hematology
    • Clinical Biochemistry

    Background:

    • Coagulation factor abnormalities are linked to liver disease.
    • Antithrombin (AT) is a key coagulation inhibitor.
    • Chronic liver disease, particularly hepatitis C, affects hemostasis.

    Purpose of the Study:

    • To assess antithrombin (AT) activity and levels in hepatitis C patients.
    • To correlate AT status with liver fibrosis severity.
    • To understand the role of AT in chronic liver disease progression.

    Main Methods:

    • Enrolled 75 patients with chronic liver disease and hepatitis C.
    • Measured AT activity and quantitative AT levels using specific reagent kits.
    • Assessed liver fibrosis severity through histological grading of liver biopsies.

    Main Results:

    • 30 out of 75 patients exhibited reduced AT activity.
    • Quantitative assays revealed decreased AT levels in 30 patients.
    • Early fibrosis stages showed normal or minimally affected AT, while advanced stages had markedly reduced AT.

    Conclusions:

    • Liver fibrosis severity significantly impacts antithrombin (AT) levels and activity.
    • Reduced AT is associated with advanced stages of liver fibrosis in hepatitis C.
    • AT status serves as a potential indicator of liver disease progression.
    Abstract

    More Related Videos

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

    Published on: February 10, 2015

    53.0K
    Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI06:09

    Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

    Published on: July 21, 2023

    1.4K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    10
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    6
    Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

    Ultrasound II: Endoscopic Ultrasound and FibroScan

    Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
    Endoscopic Ultrasound (EUS):
    221
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    5
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    975
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    8